|Bid||0.00 x 1800|
|Ask||0.00 x 1400|
|Day's Range||92.52 - 99.16|
|52 Week Range||43.29 - 125.61|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||16.64|
|Earnings Date||May 04, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||117.29|
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Medicines Agency (EMA) has validated the company's Type II variation marketing authorization application for AYVAKYT® (avapritinib) for the treatment of advanced systemic mastocytosis (SM). Validation of the application confirms that the submission is sufficiently complete to begin the formal review process. The European Commission has granted orphan medicinal product designation to AYVAKYT for the treatment of mastocytosis.
In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the healthcare industry. Biotechnology uses biology and the functions of living […]
Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share fell 13.33% over the past year to ($1.53), which beat the estimate of ($1.62). Revenue of $34,107,000 decreased by 33.82% from the same period last year, which beat the estimate of $29,240,000. Looking Ahead Blueprint Medicines hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. How To Listen To The Conference Call Date: Feb 17, 2021 View more earnings on BPMC Time: 08:30 AM ET Webcast URL: https://edge.media-server.com/mmc/p/shp6w5zy Recent Stock Performance Company's 52-week high was at $125.61 52-week low: $43.29 Price action over last quarter: down 8.88% Company Description Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 17, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.